/
Metabolic & Endocrine
Diabetes Mellitus
337
Pipeline Programs↗
988
Active Trials↗
313
Companies Involved↗
Diabetes Mellitus is a highly competitive landscape with 337 programs across 313 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Sunshine Lake Pharma Co., Ltd., Sun Pharmaceutical Industries Limited. 68 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical199
Phase 128
Phase 242
Phase 368
Approved
No programs
Analysis
Modality Breakdown
95%
Small molecule
282 of 297 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 297 classified programs, each share of the total. Modality classified for 94% of 337 pipeline programs.
Analysis
Trial Status
4,885
clinical trials
Completed3,189 · 65%
Recruiting482 · 10%
Unknown status314 · 6%
Not yet recruiting263 · 5%
Terminated255 · 5%
Active, not recruiting205 · 4%
Other177 · 4%
Clinical Trials
Trial Activity
4885 trials
Early Tracking of Childhood Health Determinants Study
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT03481829·1,500 enrolled
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
Recruiting·—·Phase 1·NCT06547619·40 enrolled
Natural History of Disorders of Insulin Resistance
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001987·1,200 enrolled
Page 1 of 326
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)